T1917 |
GSK 3 Inhibitor IX
|
667463-62-9
|
99.9%
|
|
GSK 3 Inhibitor IX (6-BIO) is a selective reversible, ATP-competitive inhibitor of GSK-3α/β and CDK1-cyclinB complex. It inhibits (GSK-3α/β)/CDK1/CDK5 activity w...
|
T0704 |
Cyanoacetohydrazide
|
140-87-4
|
99.9%
|
|
Cyanoacetohydrazide (Cyanoacetic hydrazide) is an anti-TB drug. It has also been used to derive compounds that may have antitumor properties.
|
T1755 |
LY2090314
|
603288-22-8
|
99.88%
|
|
LY2090314, an effective GSK-3α/β inhibitor (IC50: 1.5 nM/0.9 nM), may improve the efficacy of platinum-based chemotherapy regimens. LY2090314 has been used in tr...
|
T67856 |
GSK-3β inhibitor 14
|
863004-48-2
|
99.88%
|
|
GSK-3β inhibitor 14 (1,5-Benzothiazepin-4(5H)-one, 2,3-dihydro-2-methyl-5-(phenylmethyl)-) is a weak GSK-3β inhibitor, IC50﹥ 100μM.
|
T1778 |
AT7519 Hydrochloride
|
902135-91-5
|
99.88%
|
|
AT7519 Hydrochloride (AT7519 HCl) is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9.
|
T6312 |
R547
|
741713-40-6
|
99.84%
|
|
R547 (Ro 4584820) is a potent ATP-competitive inhibitor of CDK1/2/4 with Ki of 2 nM/3 nM/1 nM. It is less potent to CDK7 and GSK3α/β, while inactive to other kin...
|
T9178 |
(E/Z)-GSK-3β inhibitor 1
|
3367-88-2
|
99.8%
|
|
(E/Z)-GSK-3β inhibitor 1 is a glycogen synthase kinase 3β (GSK-3β) inhibitor and demonstrates high antidiabetic efficacy.
|
T10202 |
A 1070722
|
1384424-80-9
|
99.78%
|
|
A 1070722 is a potent and selective GSK-3 inhibitor, with a Ki of 0.6 nM for both GSK-3α and GSK-3β. It can penetrate the blood-brain barrier (BBB) and accumulat...
|
T14613 |
BIP-135
|
941575-71-9
|
99.77%
|
|
BIP-135 is a potent and selective ATP-competitive GSK-3 inhibitor. With IC50s of 16 nM and 21 nM for GSK-3α and GSK-3β, respectively. BIP 135 exhibits neuroprote...
|
T3385 |
Gypenoside XVII
|
80321-69-3
|
99.76%
|
|
Gypenoside XVII (Gynosaponin S) confers protection against Aβ25-35-induced neurotoxicity through estrogen receptor-dependent activation of PI3K/Akt pathways, act...
|
T26894 |
BRD0209
|
1597439-87-6
|
99.75%
|
|
BRD0209 is a highly selective and potent GSK3 inhibitor.
|
T61360 |
ARN25068
|
2649882-80-2
|
99.71%
|
|
ARN25068 is a potent inhibitor of GSK-3β, FYN, and DYRK1A protein kinases, exerting its activity in the sub-micromolar range. This compound effectively addresses...
|
T1741 |
AZD1080
|
612487-72-6
|
99.68%
|
|
AZD1080 is a selective, orally active, brain permeable GSK3 inhibitor.
|
T6205 |
AT7519
|
844442-38-2
|
99.67%
|
|
AT7519 is a CDK1/2/4/6/9 inhibitor (IC50: 10-210 nM). It is less effective to CDK3 and little active to CDK7.
|
T78578 |
GSK-3 Inhibitor XIII
|
404828-14-4
|
99.66%
|
|
GSK-3 Inhibitor XIII, an ATP-competitive GSK-3 inhibitor (Ki: 24 nM), can be used to study diabetes and obesity.
|
T5200 |
Indirubin-3'-monoxime
|
160807-49-8
|
99.65%
|
|
Indirubin-3'-monoxime (Indirubin-3'-oxime) is a potent inhibitor of GSK3β (IC50: 22 nM) and also inhibits CDKs ( (IC50s: 100/180/250 nM for Cdk5/p35, Cdk1/cyclin...
|
T3077 |
SB 216763
|
280744-09-4
|
99.61%
|
|
SB 216763 (SB216763) is an effective and specific GSK-3α/β inhibitor (IC50: 34.3 nM).
|
T6358 |
1-Azakenpaullone
|
676596-65-9
|
99.6%
|
|
1-Azakenpaullone (azakenpaullone) is a potent and selective GSK-3β inhibitor with IC50 of 18 nM, >100-fold selectivity over CDK1/cyclin B and CDK5/p25.
|
T3166 |
VX-11e
|
896720-20-0
|
99.6%
|
|
VX-11e (TCS ERK 11e) is a potent, selective, and orally bioavailable ERK(Extracellular Signal-Regulated Kinase) inhibitor; antitumor agent.
|
T10606 |
BRD0705
|
2056261-41-5
|
99.59%
|
|
BRD0705 is a potent, paralog selective and orally active GSK3α inhibitor (IC50: 66 nM; Kd: 4.8 μM). BRD0705 displays increased selectivity for GSK3α (8-fold) ver...
|